ORYZON presented new preclinical data of ORY-2001 therapeutic activity in Multiple Sclerosis at ACTRIMS-2017

27 February 2017 BARCELONA, SPAIN and CAMBRIDGE MA. • ORY-2001 Reduces Lymphocyte Egress and Demyelination in Experimental Autoimmune Encephalomyelitis • Data highlights the Epigenetic Axis in Multiple Sclerosis Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, presented last Friday new preclinical data of therapeutic activity in Multiple Sclerosis (MS) of ORY-2001, a novel epigenetic drug for the treatment of neurodegenerative diseases at the 2nd Annual Conference of the “Americas Committee for Treatment and Research in Multiple Sclerosis” (ACTRIMS) in Orlando, Fl. USA. Click here to see the full Press Release

The release as fetched from its publisher. oryzon.com ↗